Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5260246 | 1.00 | HTT (0.41) | HTTALDH1A1SMN1; SMN2FFAR3HDAC3 | |
| SCHEMBL14627310 | 1.00 | HTT (0.41) | HTTALDH1A1SMN1; SMN2FFAR3HDAC3 | |
| SCHEMBL11955648 | 1.00 | HTT (0.41) | HTTALDH1A1SMN1; SMN2FFAR3HDAC3 | |
| Hydrochloric Acid SCHEMBL20502497 | 0.98 | HTT (0.40) | HTTALDH1A1SMN1; SMN2FFAR3HDAC3 | |
| SCHEMBL1446029 | 0.97 | HTT (0.38) | HTTALDH1A1SMN1; SMN2FFAR3HDAC3 | |
| SCHEMBL9613245 | 0.92 | — | — | |
| SCHEMBL7991761 | 0.87 | — | — | |
| SCHEMBL1694483 | 0.80 | CNR2 (0.37) | ALDH1A1SMN1; SMN2FFAR3HDAC3HDAC1 | |
| SCHEMBL13204887 | 0.79 | POLB (0.45) | HTTALDH1A1FFAR3KMT2APOLB | |
| SCHEMBL21782563 | 0.78 | HDAC3 (0.35) | ALDH1A1SMN1; SMN2HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112661309-A | Sodium sulfate wastewater treatment system | 昆山美淼环保科技有限公司 | 2021-04-16 | — | — | CN | claimed |
| CN-111547915-A | Biochemical pretreatment system of phenol ammonia waste water | 昆山美淼环保科技有限公司 | 2020-08-18 | — | — | CN | claimed |
| CN-111547914-A | Method for recovering phenol from semi-coke wastewater | 昆山美淼环保科技有限公司 | 2020-08-18 | — | — | CN | claimed |
| CN-111547913-A | Method for recovering phenol from phenol-containing wastewater | 昆山美淼环保科技有限公司 | 2020-08-18 | — | — | CN | claimed |
| EP-0318933-A2 | Psychotropic acyclic amide derivatives, a process for preparing them and pharmaceutical compositions | Bristol-Myers Squibb Company (US) | 1989-06-07 | — | — | EP | claimed |
| WO-2023064361-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| CN-112661309-A | Sodium sulfate wastewater treatment system | 昆山美淼环保科技有限公司 | 2021-04-16 | — | — | CN | disclosed |
| CN-111547915-A | Biochemical pretreatment system of phenol ammonia waste water | 昆山美淼环保科技有限公司 | 2020-08-18 | — | — | CN | disclosed |
| CN-111547913-A | Method for recovering phenol from phenol-containing wastewater | 昆山美淼环保科技有限公司 | 2020-08-18 | — | — | CN | disclosed |
| CN-111547914-A | Method for recovering phenol from semi-coke wastewater | 昆山美淼环保科技有限公司 | 2020-08-18 | — | — | CN | disclosed |
| US-7220532-B2 | Chemical amplification type resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220532-B2 | Chemical amplification type resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-22 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| CN-1341594-A | Substituted pyrrolidone, thiazolidone or oxazolidone as herbicide | ZENECA LTD (GB) | 2002-03-27 | — | — | CN | disclosed |
| EP-0636625-B1 | Tricyclic diazepines vasopressin and oxytocin antagonists | AMERICAN CYANAMID CO (US) | 1999-01-27 | — | — | EP | disclosed |
| CN-1153512-A | Substituted pyrrolidones, thiazolidinones or oxazolidinones as herbicides | ZENECA LTD (GB) | 1997-07-02 | — | — | CN | disclosed |
| US-3960945-A | 4-[-(Alkoxy or polyhaloalkoxy)-benzamido]cyclohexanones | STERLING DRUG INC. (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | HTT 1689/4885ALDH1A1 1598/4885SMN1; SMN2 2550/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | HTT 26/4885ALDH1A1 3102/4885SMN1; SMN2 478/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | HTT 1760/4885ALDH1A1 1601/4885SMN1; SMN2 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.